Actithera: Difference between revisions
Added new company |
Added revenue data from proff.no (org 935 938 341) |
||
| Line 9: | Line 9: | ||
== What They Do == | == What They Do == | ||
Radiopharmaceutical company developing radioligand therapies for cancer treatment. Radioligand therapy targets cancer cells with radioactive compounds, offering precision treatment with fewer side effects than traditional chemotherapy.<ref>pharmaphorum (Jul 2025): "New radiopharma Actithera emerges with $75.5m in financing"</ref> | Radiopharmaceutical company developing radioligand therapies for cancer treatment. Radioligand therapy targets cancer cells with radioactive compounds, offering precision treatment with fewer side effects than traditional chemotherapy.<ref>pharmaphorum (Jul 2025): "New radiopharma Actithera emerges with $75.5m in financing"</ref> | ||
== Revenue == | |||
'''Org nr:''' 935 938 341 | |||
'''Source:''' [https://www.proff.no/selskap/actithera-norway-as/oslo/forskning-og-utvikling/IFH8EN900FV proff.no] | |||
* '''2024:''' N/A (no accounts filed) | |||
* '''Employees:''' 1-4 | |||
Founded May 2025. Radiopharmaceutical company developing radioligand therapies for cancer. Norwegian subsidiary of Actithera Group AS. US operations. $75.5M Series A (Jul 2025). | |||
== Funding == | == Funding == | ||
Latest revision as of 07:57, 14 April 2026
What They Do[edit]
Radiopharmaceutical company developing radioligand therapies for cancer treatment. Radioligand therapy targets cancer cells with radioactive compounds, offering precision treatment with fewer side effects than traditional chemotherapy.[1]
Revenue[edit]
Org nr: 935 938 341 Source: proff.no
- 2024: N/A (no accounts filed)
- Employees: 1-4
Founded May 2025. Radiopharmaceutical company developing radioligand therapies for cancer. Norwegian subsidiary of Actithera Group AS. US operations. $75.5M Series A (Jul 2025).
Funding[edit]
$75.5 million Series A (July 2025).[2]
Notably, Actithera secured this large Series A without a complete leadership team in place — defying typical VC expectations.[3] BioPharma Dive reported the company drew "new investors to radiopharma drug pitch."[4]
European Biotechnology Magazine noted the deal reflects "huge momentum" in radiopharma funding globally.[5]
See Also[edit]
- ↑ pharmaphorum (Jul 2025): "New radiopharma Actithera emerges with $75.5m in financing"
- ↑ ArcticStartup (Jul 10, 2025): "Norway & US-based Actithera raises $75.5M Series A to advance radioligand therapy pipeline"
- ↑ BioXconomy (2025): "Defying Series A odds: How Actithera secured $75.5m without a leadership team"
- ↑ BioPharma Dive (2025): "Actithera draws new investors to radiopharma drug pitch"
- ↑ European Biotechnology Magazine (2025): "Actithera: Radiopharma Funding Gathers Huge Momentum"